BioNTech SE (BNTX) Operating Leases (2021 - 2025)

BioNTech SE has disclosed Operating Leases across 5 years of filings, most recently posting $242.0 million for Q3 2025.

• Operating Leases for Q3 2025 came in at $242.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $242.0 million (changed N/A YoY), and the FY2024 annual result was $271.6 million, up 16.5% from the prior year.
• Operating Leases came in at $242.0 million for Q3 2025 at BioNTech SE, down from $260.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $274.4 million in Q3 2022 to a low of $207.7 million in Q4 2021.
• The 5-year median for Operating Leases is $253.3 million (2022), against an average of $244.9 million.
• Across the five-year window, Operating Leases gained 16.5% in 2024 and rose 2.12% in 2025, its largest moves.
• BioNTech SE's Operating Leases stood at $207.7 million in 2021, then increased by 3.18% to $214.4 million in 2022, then grew by 8.77% to $233.2 million in 2023, then grew by 16.5% to $271.6 million in 2024, then decreased by 10.91% to $242.0 million in 2025.
• The last three Operating Leases figures came in at $242.0 million (Q3 2025), $260.5 million (Q2 2025), and $259.6 million (Q1 2025), per Business Quant data.